Indication
As monotherapy for the treatment of locally advanced or metastatic or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy (first line)

Medicine details

Medicine name:
pembrolizumab (Keytruda) (urothelial carcinoma)
SMC ID:
1339/18
Pharmaceutical company
MSD
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Advice due date:
10 September 2018
SMC meeting date:
07 August 2018
Patient group submission deadline:
02 April 2018